Trial Profile
A randomised, double blind, parallel, placebo controlled, drug-drug interaction study to investigate the safety, tolerability and pharmacokinetics of multiple doses of HTL0018318 given alone and in combination with donepezil at steady state in elderly volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Jul 2021
Price :
$35
*
At a glance
- Drugs HTL 18318 (Primary) ; Donepezil
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Heptares Therapeutics
- 23 Jun 2021 Results assessing the safety and tolerability and pharmacokinetics of repeated doses of HTL0018318 (15 or 25 mg) given without and in combination with donepezil, published in the Drugs in R and D.
- 05 Aug 2017 Status changed from not yet recruiting to completed.
- 23 Feb 2017 New trial record